| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Collaboration revenue | 1,225 | 1,115 | 1,454 | 209 |
| Research and development | 43,990 | 41,375 | 40,562 | 40,340 |
| General and administrative | 11,208 | 13,117 | 13,284 | 14,101 |
| Total operating expenses | 55,198 | 54,492 | 53,846 | 54,441 |
| Loss from operations | -53,973 | -53,377 | -52,392 | -54,232 |
| Interest income | 1,141 | 743 | 1,182 | 697 |
| Amortization of premiums and discount on short-term investments | 752 | 530 | 339 | 885 |
| Change in fair value of short-term investment related party | 1,454 | -505 | -1,056 | 215 |
| Other income, net | 44 | 18 | 37 | -83 |
| Total other income, net | 3,391 | 786 | 502 | 1,714 |
| Net loss before income taxes | - | -52,591 | -51,890 | -52,518 |
| Provision for income taxes | - | 0 | - | - |
| Net loss attributable to common stockholders, basic | -50,582 | -52,591 | -51,890 | -52,518 |
| Net loss attributable to common stockholders, diluted | -50,582 | -52,591 | -51,890 | -52,518 |
| Net loss per share attributable to common stockholders, basic (in dollars per share) | -0.32 | -0.41 | -0.4 | -0.44 |
| Net loss per share attributable to common stockholders, diluted (in dollars per share) | -0.32 | -0.41 | -0.4 | -0.44 |
| Weighted-average common shares outstanding, basic (in shares) | 160,503,183 | 129,185,918 | 130,884,490 | 119,764,270 |
| Weighted-average common shares outstanding, diluted (in shares) | 160,503,183 | 129,185,918 | 130,884,490 | 119,764,270 |
Prime Medicine, Inc. (PRME)
Prime Medicine, Inc. (PRME)